Charles River Laboratories | CRL - Current Liabilities

Stock Price
169.80
Daily Change
2.06 1.23%
Monthly
2.36%
Yearly
48.09%
Q2 Forecast
166.17

Charles River Laboratories reported $1.12B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Agilent USD 2.23B 113M Dec/2025
Align Technology USD 1.92B 46.45M Dec/2025
Bio-Rad Laboratories USD 517M 5.3M Dec/2025
Bruker USD 1.28B 11.1M Dec/2025
Cardinal Health USD 43.31B 3.05B Dec/2025
Charles River Laboratories USD 1.12B 1.57M Dec/2025
Cigna USD 56.34B 111M Dec/2025
Concord Medical Services Hldg CNY 2.45B 1.12B Jun/2025
CVS Health USD 88.69B 4B Dec/2025
Danaher USD 7.46B 653M Mar/2026
Dentsply International USD 1.34B 62M Dec/2025
Elevance Health USD 45.31B 4.27B Mar/2026
Galapagos EUR 152.86M 213.7M Dec/2025
Humana USD 16.35B 166M Dec/2025
Illumina USD 1.59B 377M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Intrexon USD 23.02M 38K Jun/2024
IQVIA Holdings USD 8.34B 170M Dec/2025
Laboratory Of America USD 2.82B 194.3M Dec/2025
Lonza CHF 3.57B 421M Dec/2025
McKesson USD 68.13B 100M Dec/2025
Merck EUR 9.04B 405M Dec/2025
Mettler Toledo International USD 1.2B 5.99M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Quest Diagnostics USD 2.18B 101M Mar/2026
Revvity USD 1.33B 108.5M Dec/2025
Thermo Fisher Scientific USD 14.62B 568M Mar/2026
United Therapeutics USD 560.6M 14.3M Dec/2025
UnitedHealth USD 114.9B 629M Dec/2025
Veradigm USD 230.31M 22.78M Dec/2022
Waters USD 1.24B 11.8M Dec/2025
West Pharmaceutical Services USD 674M 19.1M Mar/2026